Menu
Close
Global
×

Company News

Company News
Company News
2026-01-07
ImmuneOnco Announces IND Acceptance for IMM0306 (Amouravfop Alfa) Monotherapy in Primary Membranous Nephropathy, Advancing Comprehensive Autoimmune Pipeline
NMPA has officially accepted the IND for IMM0306 monotherapy in Primary Membranous Nephropathy (PMN).
View more
2026-01-06
ImmuneOnco Regains Global Rights to IMM2510/AXN-2510 and IMM27M/AXN-27M Following Axion Bio's Discontinuation
SHANGHAI, January 6, 2026 -- ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX: 1541.HK) ("ImmuneOnco") today announced that Axion Bio, Inc. (“Axion”), a wholly-owned subsidiary of Instil Bio, Inc.,
View more
2026-01-05
ImmuneOnco R&D Vice President Mr. Li Song Selected for Shanghai's 2025 "Oriental Talent Program"
Recently, the list of selected candidates for the 2025 Shanghai "Oriental Talent Program" (Top Tier) was officially announced. Mr. Li Song, Vice President of Research and Development at ImmuneOnco Bio
View more
2025-12-15
ImmuneOnco Successfully Holds Interim Investigator Meeting in Beijing for Phase Ib/II Clinical Study of Amulirafusp Alfa (IMM0306) Injection in Active Systemic Lupus Erythematosus
ImmuneOnco successfully convened the interim investigator meeting for the "Phase Ib/II Clinical Study of Amulirafusp Alfa (IMM0306) Injection in Active Systemic Lupus Erythematosus (SLE)" in Beijing.
View more
2025-12-09
2025 ASH | ImmuneOnco Announces Positive Progress from Phase I/II Study of IMM0306 Combined with Lenalidomide for Relapsed/Refractory CD20-Positive Follicular Lymphoma
December 9, 2025 – ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (hereinafter referred to as "ImmuneOnco", Hong Kong Stock Exchange code: 01541.HK) today announced that the company presented data from
View more
2025-11-27
ImmuneOnco's Amulirafusp Alfa (IMM0306) Phase III Clinical Trial Protocol Approved by CDE, Accelerating Development of Novel Therapy for Relapsed/Refractory Follicular Lymphoma
Amulirafusp Alfa (IMM0306), in combination with lenalidomide for the treatment of relapsed/refractory follicular lymphoma (FL), has been formally approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA)
View more
总计 84 12345678...1314